Innovation in Immunity: Accelerating T-Cell Recovery in Allogeneic HSCT
Thursday, May 30, 2024 08:00 AM - 09:00 AM
Room 208-209
Roundtable
Organized by: ISCT Stem Cell Engineering Committee
Moderators
As immune reconstitution drives all outcomes post-allogeneic transplantation, discuss the innovative strategies and engineering techniques that maximize this reconstitution.
Key Learning Objectives
1. Post-HSCT T-cell reconstitution includes two main components: thymus-dependent and thymus- independent IR. While the production of new T cells from progenitors via thymopoiesis is crucial to maintain an adequate long-term IR, especially in the first 100 days post-HSCT the homeostatic expansion of T cells adoptively transferred with the graft is essential to prevent life-threatening infections and leukemia relapse.
2. We'll explore various strategies to boost thymus-independent IR post-transplant, particularly when naive T-cell production is impaired. We'll discuss donor leukocyte infusions, adoptive transfer of non-alloreactive T cells, transitions of suicide gene-transduced T cells, and infusions of pathogen-specific and regulatory T cells. These innovative methods are designed to enhance patient prognosis during the critical post-transplant period.
3. We aim to shed light on modifying by using targeted approaches the conditioning regimen to maximize the function of cells transferred with the graft as well as thymus-dependent IR.
Moderators
- Alice Bertaina, MD, PhD, Stanford School of Medicine, United States
- Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, United States
- Sarah Nikiforow, MD, PhD, Dana-Farber Cancer Institute, United States
- Megan Levings, PhD, The University of British Columbia, Canada
- Everett Mayer, MD, PhD, Stanford School of Medicine, United States
As immune reconstitution drives all outcomes post-allogeneic transplantation, discuss the innovative strategies and engineering techniques that maximize this reconstitution.
Key Learning Objectives
1. Post-HSCT T-cell reconstitution includes two main components: thymus-dependent and thymus- independent IR. While the production of new T cells from progenitors via thymopoiesis is crucial to maintain an adequate long-term IR, especially in the first 100 days post-HSCT the homeostatic expansion of T cells adoptively transferred with the graft is essential to prevent life-threatening infections and leukemia relapse.
2. We'll explore various strategies to boost thymus-independent IR post-transplant, particularly when naive T-cell production is impaired. We'll discuss donor leukocyte infusions, adoptive transfer of non-alloreactive T cells, transitions of suicide gene-transduced T cells, and infusions of pathogen-specific and regulatory T cells. These innovative methods are designed to enhance patient prognosis during the critical post-transplant period.
3. We aim to shed light on modifying by using targeted approaches the conditioning regimen to maximize the function of cells transferred with the graft as well as thymus-dependent IR.
Jaap Jan Boelens
Chief Transplantation and Cellular Therapies
Memorial Sloan Kettering Cancer Center
Moderator
Chief Transplantation and Cellular Therapies
Memorial Sloan Kettering Cancer Center
Moderator
Sarah Nikiforow
Medical Director, Cell Manipulation Core Facility
Dana Farber Cancer Institute
Panelist
Medical Director, Cell Manipulation Core Facility
Dana Farber Cancer Institute
Panelist